What Ultibro Breezhaler treats: Main Uses and Benefits

The medication is primarily prescribed as a long-term maintenance treatment for adult patients with Chronic Obstructive Pulmonary Disease (COPD). It is relevant for managing the persistent airflow limitation that defines this condition and contributes to stable disease management.

The primary therapeutic focus is on addressing symptoms related to COPD, including chronic shortness of breath (dyspnea) and the uncomfortable feeling of airway obstruction. It is commonly used in clinical settings that involve chronic symptom patterns and is applied during phases when symptoms become more noticeable.

Quick Fact: Relief for Respiratory Symptoms

Category	Description
Primary Indication	Chronic Obstructive Pulmonary Disease (COPD)
Symptom Focus	Chronic shortness of breath, airflow limitation
Goal	Supports maintenance therapy, eases symptom burden

The medication is considered relevant for easing symptoms that interfere with daily functioning and patient comfort. The medication may assist with managing exercise intolerance and supports patients in performing routine daily activities by easing the symptoms that interfere with daily functioning.

Regulatory References

1. European Medicines Agency (EMA) therapeutic overview

Eligibility for Ultibro Breezhaler Use

Ultibro Breezhaler is officially approved for use in adult patients aged 18 years and older for the long-term maintenance treatment of Chronic Obstructive Pulmonary Disease (COPD). Use in the pediatric population (under 18 years of age) is not recommended, as its safety and efficacy have not been established by regulatory bodies.

Classification	Population or Condition
Contraindicated	Patients with hypersensitivity to the active ingredients or excipients.
	Patients with asthma (LABA component is contraindicated for asthma monotherapy).
	Patients with rare hereditary problems of galactose intolerance or lactase deficiency.
Conditional Use	Patients with severe renal impairment or end-stage renal disease.
	Patients with narrow-angle glaucoma or urinary retention.
	Patients with certain cardiovascular disorders or severe hepatic impairment.
Not Recommended	Use during pregnancy or while breastfeeding.

Usage is not indicated for the relief of acute episodes of bronchospasm or rapidly deteriorating COPD. For patients with severe kidney impairment, the regulatory guidance states the medicine should only be used if the expected benefit outweighs the potential risk. Similarly, caution is required for individuals with specific pre-existing conditions like convulsive disorders or thyrotoxicosis.

Interactions with other medicines and products

The official regulatory profile for Ultibro Breezhaler is structured by documented restrictions and pharmacokinetic pathways related to its dual active components, Indacaterol (LABA) and Glycopyrronium (LAMA).

Interaction Classification	Documented Constraint
Additive Pharmacodynamic Interaction	Co-administration with other Long-Acting Beta-Adrenergic Agonists (LABA) or other anticholinergic-containing medicines is officially not recommended due to the potential for excessive additive effects [EMA SmPC].
Pharmacodynamic Risk Factors	Concomitant use with Beta-Blockers (including eye drops) may antagonize the bronchodilatory effect and is generally restricted unless compelling reasons exist. The label notes caution with QTc-prolonging medicines, Sympathomimetic agents, and treatments that may potentiate hypokalaemia (such as methylxanthine derivatives, steroids, or non-potassium-sparing diuretics).
Metabolic/Transporter-Mediated	Potent combined inhibitors of CYP3A4 and P-glycoprotein (P-gp), such as Ketoconazole, increase the systemic exposure (plasma levels) of Indacaterol. Inhibitors of organic cation transport, such as Cimetidine, are documented to increase Glycopyrronium exposure; however, these changes are not expected to be clinically relevant at recommended doses [FDA Prescribing Information].
Excipient Interaction	The medicine is officially contraindicated in patients with a severe hypersensitivity to milk proteins, which is linked to the lactose excipient in the inhalation powder [EMA SmPC].

Population-Specific Interaction Notes:

Regulatory documents state that patients with severe renal impairment (eGFR below 30 ml/min/1.73 m^2) show an increased total systemic exposure (AUC) to the Glycopyrronium component (up to 2.2-fold). The use of the medicine in this population should follow a careful benefit-risk assessment. No specific administration-timing rules are documented for co-administered drugs.

Dual-Targeted Airway Relaxation

This medicine exerts its effect by simultaneously engaging two distinct receptor systems on the airway smooth muscle. One component acts as an antagonist (blocker) of the Muscarinic M3 receptor, while the other acts as an agonist (activator) of the Beta-2 adrenergic receptor. This dual-action approach modulates receptor systems that regulate airway smooth muscle tone.

---

Molecular Control of Muscle Tone

By acting as an antagonist at the M3 receptor and an agonist at the Beta-2 receptor, the agents modulate their respective intracellular signaling cascades. It prevents the increase in calcium that normally initiates muscle contraction and increases cyclic AMP (cAMP) which promotes muscle relaxation. This combined action on molecular pathways results in prolonged bronchodilation.

---

Resulting Physiological Dynamics

The synergistic effect, achieved by M3 antagonism and Beta-2 agonism, results in a decrease in airway resistance. This modulation establishes a physiological state characterized by wider airway caliber.

Administration Protocol

Ultibro Breezhaler is prescribed for long-term maintenance treatment and must be used as a once-daily, single-capsule dose every day, regardless of symptom presence. The recommended regimen is based on the inhalation of the contents of one hard capsule per day, with the delivered dose being 85 micrograms of Indacaterol and 43 micrograms of Glycopyrronium. Patients must be instructed not to exceed the maximum daily dose of one capsule.

Instruction	Detail
Route of Administration	Oral inhalation only. The capsule contents must not be swallowed.
Dosing Frequency	Once daily (q.d.), ideally at the same time each day.
Missed Dose Rule	If a dose is missed, it should be taken as soon as possible on the same day, but no more than one dose should be inhaled in a single day.
Administration Device	Must be administered only using the Ultibro Breezhaler inhaler provided with the pack.
Timing & Food	Can be inhaled before or after food or drink.

Population-Specific Use and Procedural Constraints

The medicine can be used at the standard recommended dose in elderly patients (75 years of age and older) and those with mild to moderate kidney impairment. However, in cases of severe renal impairment or end-stage renal disease, use should only proceed after careful assessment. There is no relevant use established for the paediatric population (under 18 years).

Procedurally, the capsule must be removed from its blister immediately before use. The Breezhaler device ensures correct administration, and the medicine must not be used with any other inhaler.

Research evidence / Overview of studies for Ultibro Breezhaler

Evidence for Use in Chronic Obstructive Pulmonary Disease (COPD)

Research evidence for this medicine focuses on adults with Chronic Obstructive Pulmonary Disease (COPD) and is primarily composed of Randomized Controlled Trials (RCTs) with extended follow-up durations. These studies included comparisons against a dummy inhaler (placebo) and against inhalers containing single active components or other combination treatments. Research examined the medicine for its use in patients whose condition is characterized by functional limitations and periods where symptoms may vary in intensity.

The researchers studied outcomes related to physical discomfort and systemic or functional imbalance, with a primary focus on lung function. Studies explored how the main measure of lung capacity, FEV1, evolved in the observed populations over time. The findings describe patterns observed in the studies where measurements of FEV1 were documented across follow-up periods lasting up to 64 weeks, including evaluations against its individual components alone and against placebo. These findings help contextualize how the medicine was evaluated under the specific conditions established during the clinical trials.

---

Research on Exacerbations and Quality of Life

The clinical trials included evaluations of outcomes describing episodic or acute changes in the condition, specifically monitoring the frequency of COPD flare-ups, known as exacerbations. Studies exploring these episodes where symptoms become more noticeable were conducted during periods with varying symptom burdens. For example, the rate of all COPD exacerbations was examined in studies that used a specific existing combination therapy as an active control in one major long-term study.

Other research explored patient-reported outcomes describing perceived discomfort, such as changes in shortness of breath (dyspnea), which was measured using standardized functional scales. Studies monitored patient-reported outcomes describing perceived discomfort when evaluated against active monotherapies; regulatory assessments of some differences reported considered the change to be small.

---

Long-Term Studies and Follow-Up Data

This segment will characterize the duration of the major clinical trials, describing the available evidence regarding outcomes measured over intermediate (26-week) and extended (up to 64-week) follow-up periods.

Long-term outcomes are not fully established for periods exceeding the 64-week trial duration, and there is limited information for outcomes extending past the completion of the core clinical development program.

---

Research Gaps and Areas of Uncertainty

This final part will synthesize documented limitations in the clinical evidence base, including which specific populations were excluded from long-term studies and where regulatory assessments noted that the clinical importance of some findings remains uncertain.

Certainty remains low for specific groups because the clinical trials often excluded patients with a history of other significant health issues, such as asthma or certain types of severe cardiovascular disease. This means that data for certain groups remain insufficient, and research has not fully established patterns for these specific patient populations.

Common questions about Ultibro Breezhaler (FAQ)

Q: What is the main difference between Ultibro Breezhaler and a single inhaler like Spiriva?

A: Ultibro Breezhaler is classified as a fixed-dose combination, meaning it contains two different active bronchodilators: a LAMA (Long-Acting Muscarinic Antagonist) and a LABA (Long-Acting Beta-Agonist). By contrast, Tiotropium (known by the brand name Spiriva) is a single-agent LAMA. Pharmacological studies support the combination’s ability to provide a more comprehensive bronchodilation effect compared to a LAMA or LABA used alone.

Q: Is Ultibro Breezhaler considered a steroid?

A: Official product information confirms that Ultibro Breezhaler is classified as a combination bronchodilator. The active ingredients are Glycopyrronium and Indacaterol. It does not contain an inhaled corticosteroid (often called a steroid).

Q: How quickly should I feel the full effects after starting Ultibro Breezhaler?

A: Clinical studies indicate that the bronchodilating effect, which helps open the airways, starts within 5 minutes of inhaling the medicine. It is important to remember that this medicine is intended for once-daily long-term maintenance treatment, meaning its purpose is to provide sustained benefit over time, not to provide immediate relief from sudden breathing difficulties.

Q: Is it normal to have a dry mouth when using the Breezhaler device?

A: According to official regulatory documents, dry mouth is listed as a common adverse reaction associated with this medicine. This means that based on clinical trials, it may affect up to 1 in 10 people.

Q: Does Ultibro Breezhaler affect blood pressure?

A: Official documents note that clinically significant cardiovascular effects have been documented, including increases in pulse rate and blood pressure. Regulatory documents include warnings for individuals with pre-existing cardiovascular disorders.

Q: Is Ultibro Breezhaler okay to use if I have glaucoma?

A: Regulatory guidance advises caution for patients with pre-existing narrow-angle glaucoma due to the risk of worsening the condition, which is a potential anticholinergic effect of one of the active ingredients. If a patient has a history of glaucoma, regulatory guidance recommends that the potential use be discussed with a healthcare professional.

Q: Can Ultibro Breezhaler affect sleep or cause insomnia?

A: Insomnia, or trouble sleeping, is listed as an uncommon adverse reaction in official regulatory documents. An uncommon adverse reaction is defined as potentially affecting up to 1 in 100 people.

Q: Does Ultibro Breezhaler have any effect on blood sugar levels?

A: The official safety profile lists Hyperglycaemia (increased blood sugar levels) and Diabetes Mellitus as common side effects. Regulatory guidance advises caution for use in patients with pre-existing diabetes mellitus.

Q: What information is available about Ultibro Breezhaler and pregnancy or breastfeeding?

A: Official regulatory documents state that use during pregnancy and while breastfeeding is generally not recommended. If the use is being considered, it is subject to a careful assessment of the potential benefits and risks.

Q: What are the long-term effects of using Ultibro Breezhaler daily?

A: Regulatory evaluations have included safety data from long-term clinical trials that extended up to 64 weeks. However, official documents note that long-term outcomes extending past this trial duration are not fully established in the current evidence base.

Q: Can Ultibro Breezhaler cause muscle cramps?

A: The official safety profile lists Musculoskeletal pain as a common side effect of the medicine. Additionally, one of the active ingredients (LABA) is associated with a class effect known as hypokalaemia (low potassium), which may potentially lead to muscle weakness or cramping.

Q: Are there any known food or drink restrictions while using this medicine?

A: According to the official administration guidelines, the medicine can be inhaled before or after food or drink. There are no specific food or drink restrictions listed in the product information.

Q: Does Ultibro Breezhaler contain lactose?

A: Official regulatory documents confirm that the inhalation powder contains lactose as an excipient (an inactive ingredient). For this reason, the medicine is contraindicated for patients with certain rare hereditary conditions such as severe lactase deficiency.

Q: What should I do if the powder gets stuck in my throat after inhaling?

A: Official patient information emphasizes the need for proper inhalation technique to ensure the medicine reaches the lungs. A patient warning notes that a lack of expected improvement in breathing may indicate improper inhalation technique, such as swallowing the medicine instead of inhaling it.

Q: Is Ultibro Breezhaler safe to use if I am driving or operating machinery?

A: Official patient information advises users to exercise caution before driving or using any machines or tools. This caution is due to the possibility of experiencing side effects, such as dizziness, until a person understands how the medicine affects them.

Q: Can the ingredients in Ultibro Breezhaler show up in drug testing?

A: Indacaterol, one of the active ingredients, belongs to the Long-Acting Beta-Agonist (LABA) drug class. The use of LABAs is subject to regulation by sports anti-doping authorities. Any concerns regarding drug testing should be checked against current regulatory anti-doping rules.

Q: Is it okay to stop using Ultibro Breezhaler if I feel better?

A: Ultibro Breezhaler is officially approved for long-term maintenance treatment of Chronic Obstructive Pulmonary Disease (COPD). Regulatory information states that the medicine should be used daily as prescribed to maintain its benefit, and stopping the medicine should only be done following consultation with a healthcare professional.

Q: Are there any warnings about using alcohol while taking Ultibro Breezhaler?

A: The official patient information recommends that individuals inform their doctor if alcohol is regularly consumed. There are no specific blanket restrictions or contraindications regarding the use of alcohol in the regulatory documents.

Q: What is the difference between Glycopyrronium and Tiotropium?

A: Both Glycopyrronium (one of the active ingredients in Ultibro Breezhaler) and Tiotropium are classified in the same drug class: Long-Acting Muscarinic Antagonists (LAMA). They are both used for the maintenance treatment of COPD.

Q: Are there any known interactions with common over-the-counter pain relievers?

A: The official interaction profile lists specific prescription drug classes, such as Beta-Blockers and QTc-prolonging medicines, as potential concerns. It does not list specific common over-the-counter pain relievers.

Q: Does Ultibro Breezhaler help improve exercise tolerance?

A: While clinical trials mainly focus on lung function measurements, they also included evaluations of patient-reported outcomes for shortness of breath (dyspnea) and overall quality of life. These factors are related to a person's ability to perform physical activities.

Q: Why is proper inhalation technique so important for the Breezhaler?

A: Proper technique is crucial because the medicine’s effectiveness relies on the inhalation powder successfully reaching the lungs. Official patient information notes that lack of improvement in breathing may occur if the medicine is swallowed rather than properly inhaled, emphasizing the importance of technique.

Q: Does using Ultibro Breezhaler carry a risk of fungal infections in the mouth?

A: The risk of oropharyngeal candidiasis (a fungal infection) is primarily associated with inhaled corticosteroids (ICS). Since Ultibro Breezhaler is a non-corticosteroid combination bronchodilator (LAMA/LABA), this specific side effect is not listed in its adverse reaction profile.

Q: Is there a public registry of adverse events reported for Ultibro Breezhaler?

A: Regulatory agencies like the European Medicines Agency (EMA) and the U.S. FDA maintain systems for monitoring the safety of authorized medicines. These agencies use established risk management plans to continuously collect and assess adverse event reports from the public and healthcare professionals.

Storage and Disposal of Ultibro Breezhaler

Ultibro Breezhaler capsules must be stored under specific regulatory conditions to protect the inhalation powder from environmental degradation.

Storage Requirements

The medicine must be stored below 25°C. The capsules must always remain in the original blister pack until the moment of use to protect them from both moisture and light. It is mandatory to keep the medicine out of the sight and reach of children.

Handling Constraint	Requirement
Container Integrity	Remove the capsule only immediately before use
Inhaler Lifespan	Dispose of the Breezhaler device after 30 days of use

Official Disposal Rules

Expired or unwanted medicine, including unused capsules and the residual inhaler, must be returned to a pharmacy for safe disposal. The empty capsule shell remaining after inhalation may be placed in household waste.